What patent does “SMOFlipid” refer to?
SMOFlipid is a brand name for a mixed-lipid intravenous emulsion (containing soybean oil, medium-chain triglycerides, olive oil, and fish oil). The “SMOFlipid patent” usually means one or more patents covering the specific lipid formulation and/or the manufacturing approach used for this mixed-lipid emulsion. The exact patent numbers depend on the country, the specific claims (composition vs. process), and the time period of the marketing authorization.
If you tell me the country (e.g., US, EU, UK, Canada, India) or share a patent number/link you found, I can map what it covers and where it fits to SMOFlipid.
How long does a Smoflipid patent last (and when would it expire)?
Patent life typically runs 20 years from the earliest priority filing for a given patent family, but the effective “market exclusivity” timing can differ from patent expiry because of:
- Patent term adjustments/ extensions (country-specific)
- Separate patents for different aspects (composition, ratios, production, packaging, or new clinical uses)
- Regulatory exclusivity regimes (not always identical to patent expiry)
Without the specific patent identifier (or jurisdiction), I can’t state an expiry date for the SMOFlipid-related patent(s).
Are there multiple patents for SMOFlipid?
Yes. Products like SMOFlipid often have a portfolio rather than a single patent, commonly including:
- Composition/ratio claims (the mix of different oils)
- Emulsion or processing claims (how it is made)
- Downstream patents (e.g., related formulations, improvements, or combinations)
So “the SMOFlipid patent” could refer to several different documents with different expiry timelines.
Can generic or biosimilar versions enter before patent expiry?
For drug products like lipid emulsions, competitors generally need to avoid the specific claims that are still in force. If a company can produce a version that does not infringe active claims (or if patents expire/are invalidated), entry can happen before every other patent in a portfolio expires. In practice, entry timing is usually driven by:
- Which patents are still enforceable
- Whether regulators approve a “generic” equivalent (where applicable)
- Patent litigation or settlements
Are there patent challenges or litigation involving SMOFlipid?
Patent disputes are common when a manufacturer wants to launch an alternative emulsion while relevant composition/process patents are still active. Whether SMOFlipid has had challenges depends on the jurisdiction and the specific patent(s) asserted. If you provide the country or the case/patent number, I can summarize what happened and the current status.
What do patients and clinicians care about with SMOFlipid patents?
Patients mostly care that an alternative product is effective and safe (especially for parenteral nutrition use in hospitals). Patent matters mainly affect:
- Availability and pricing of lipid emulsions
- Which formulations are approved as equivalents
- Safety/quality consistency for production methods that a manufacturer must follow once alternatives enter
If you want, I can identify the exact SMOFlipid patent(s)
Reply with one of the following, and I’ll pull together the key facts for that specific “SMOFlipid patent”:
1) Country (US/EU/UK/Canada/etc.)
2) Any patent number(s) you have
3) A link to the patent or a regulatory label/approval page
4) The product strength/format (if known), since different versions can map to different patents